Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

21
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
21
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

1.4K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
1.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

25
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
25
Antimicrobial Proteins01:23

Antimicrobial Proteins

9.2K
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
9.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

21
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
21
The Periodic Table and Organismal Elements00:57

The Periodic Table and Organismal Elements

191.3K
Overview
191.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cu-porphyrin PCN-222 MOF hybridized with Au nanoclusters to accelerate electron transfer for ultrasensitive detection of 25-hydroxyvitamin D<sub>3</sub>.

Bioelectrochemistry (Amsterdam, Netherlands)·2026
Same author

Electrochemical detection of miRNA-128 in Alzheimer's disease using (3-aminopropyl) triethoxysilane and citrate-capped green-synthesized silver nanoparticles.

Mikrochimica acta·2026
Same author

MOF-metal nanohybrid-assisted charge transfer amplification for electrochemical biosensing of the MUC1 cancer biomarker.

The Analyst·2026
Same author

Metallosurfactant-based surface modification of biomedical alloys for inhibiting BSA adsorption and microbial corrosion.

Bioelectrochemistry (Amsterdam, Netherlands)·2026
Same author

Mesoporous silica supported Au-Cu bimetallic nanoparticles-based electrochemical aptasensor for estimation of ampicillin in milk.

Talanta·2025
Same author

<i>Tagetes erecta</i> synthesized bimetallic Ag-Au nanoparticles and their potential application in electrochemical detection and estimation of ampicillin in raw milk.

RSC advances·2025

Related Experiment Video

Updated: Oct 14, 2025

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

5.0K

Iron disorders and hepcidin.

Shilpa Rana1, Nirmal Prabhakar1

  • 1Department of Biochemistry, Sector-25, Panjab University, Chandigarh 160014, India.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|November 10, 2021
PubMed
Summary
This summary is machine-generated.

Hepcidin, a key regulator of iron metabolism, shows promise as a biomarker for disease prediction and a therapeutic target for iron disorders. Recent advancements focus on analytical techniques and drug development for better iron management.

Keywords:
AgonistsAntagonistsBiosensorELISAHepcidinMass spectrometry

More Related Videos

Measurement of Heme Synthesis Levels in Mammalian Cells
09:43

Measurement of Heme Synthesis Levels in Mammalian Cells

Published on: July 9, 2015

12.2K
Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

616

Related Experiment Videos

Last Updated: Oct 14, 2025

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay
05:08

Measurement of Tissue Non-Heme Iron Content using a Bathophenanthroline-Based Colorimetric Assay

Published on: January 31, 2022

5.0K
Measurement of Heme Synthesis Levels in Mammalian Cells
09:43

Measurement of Heme Synthesis Levels in Mammalian Cells

Published on: July 9, 2015

12.2K
Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism
05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

616

Area of Science:

  • Biochemistry
  • Physiology
  • Pharmacology

Background:

  • Iron is vital for physiological processes, necessitating strict homeostasis to prevent deficiency or overload.
  • Hepcidin, a liver-synthesized peptide hormone, is the primary regulator of systemic iron metabolism.
  • Dysregulation of iron homeostasis is linked to conditions like iron deficiency anemia and iron overload disorders.

Purpose of the Study:

  • To review recent advancements in analytical techniques for hepcidin measurement.
  • To explore emerging therapeutic strategies targeting hepcidin for iron disorders.
  • To highlight hepcidin's potential as a diagnostic biomarker and therapeutic agent.

Main Methods:

  • Review of immunochemical assays, mass spectrometry, and biosensor technologies for hepcidin detection.
  • Analysis of current and developing hepcidin-targeting drugs, including agonists, stimulators, and antagonists.
  • Synthesis of recent literature on hepcidin's role in iron metabolism and disease.

Main Results:

  • Analytical techniques for hepcidin measurement have seen significant recent development.
  • Hepcidin-targeting drugs demonstrate potential as effective therapeutic agents for iron disorders.
  • Hepcidin's role as a biomarker and therapeutic target is increasingly recognized.

Conclusions:

  • Hepcidin is a critical regulator of iron metabolism with significant clinical implications.
  • Advancements in analytical methods and drug development are enhancing hepcidin's utility in managing iron disorders.
  • Hepcidin represents a promising target for novel diagnostics and therapeutics in iron-related diseases.